ClinicalTrialsFinder
CompletedPhase 1ACTRN12608000521325

Epstein-Barr Virus (EBV) -specific T cells as therapy for relapsed / refractory EBV-positive lymphomas

Epstein-Barr Virus (EBV)-specific T cells as therapy for relapsed/refractory EBV-positive lymphomas

Sponsor

Queensland Institute of Medical Research (QIMR)

Enrollment

20 participants

Start Date

Oct 23, 2008

Study Type

Interventional

Conditions

Relapsed or refractory EBV-positive lymphoma

Summary

This trial will use a new method of treating lymphoma using a therapy derived from a person’s Killer T cells. These Killer T cells are taken from a person's blood and grown in a test tube to increase the number of these cells that are specifically active against the lymphoma cells. The cells are then given to the patient by intravenous infusion with the aim of killing the lymphoma cells. Potentially this treatment will help to kill the residual/recurrent tumour that is present after other lymphoma treatment and reduce the chance of the tumour recurring.

Eligibility

Sex: Both males and femalesMin Age: 18 Yearss

Inclusion Criteria7

  • Informed consent.
  • EBV-positive lymphoma as determined by in situ hybridization or equivalent (excluding Burkitts Lymphoma).
  • Age 18 years or older.
  • Eastern Cooperative Oncology Group (ECOG) performance status 1, 2 or 3
  • Life expectancy of at least 6 months.
  • Measurable disease: either relapsing, partially responsive, refractory or progressive disease, includes disease detected either by clinical examination, radiographic evaluation (including CT scans, and at physician’s discretion by functional imaging), or a persistently detectable plasma EBV viral load.
  • No chemotherapy / radiotherapy and/or antibody therapy for at least 2 weeks prior to anticipated date of first infusion.

Exclusion Criteria7

  • EBV negative tumour.
  • Presence of detectable malignant cells in the peripheral circulation by flow cytometry or morphology.
  • Serious infection within the past 28 days that has not adequately responded to therapy.
  • Pregnancy, or unwilling to use adequate contraception.
  • Serology (taken within 3 months of CTL release date) indicating active HBV or HCV infection, positive serology for HIV I&II, HTLV1 or syphilis.
  • Negative serology for EBV.
  • Psychiatric, addictive or any condition which may compromise the ability to participate in this trial

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

Autologous AdE1-Latent Membrane Protein (LMP) Cytotoxic T Lymphocytes. Dose, duration and mode of administration: total dose 20-800 million CTL given in 4 equal doses (each dose 5-200 million CTL) i

Autologous AdE1-Latent Membrane Protein (LMP) Cytotoxic T Lymphocytes. Dose, duration and mode of administration: total dose 20-800 million CTL given in 4 equal doses (each dose 5-200 million CTL) intravenously, at weekly intervals for the first cohort of 10 patients, and twice a week for the second cohort of ten patients.

Locations(1)

Australia

View Full Details on ANZCTR

For the most up-to-date information, visit the official listing.

Visit

ACTRN12608000521325